Slides
Page 1
Orchid Pharma LimitedFinancials Q3 & 9M FY-26 •All results in standalone basis.•These are approx. figures, for exact nos. please refer financials for details
Page 2
Financial Performance(Amt. in Cr.) Q3-26 Q3-25 Change % 9M-26 9M-25 % ChangeSales207 217-5%574 684-16%Other Income11 10+10%42 26+62%COGS143 124 374 406Employee Exp23 22+5%69 64+8%Other Exp38 44-14%114 125-9%EBITDA*13 37-65%58 115-50%% to Sales6% 17% 10% 17%Interest 3 4-25%10 11-9%Depreciation9 9 26 26Exceptional Items7 0 7 0PBT & PAT-6 24 15 78
Page 3
Turnover (Amt. in Cr.) 159 160 221 217 207 - 50 100 150 200 250 Q3-22 Q3-23 Q3-24 Q3-25 Q3-26
Page 4
EBIDTA & PBT as % to Sales Q3 11%14%19%17%6%-6%4%14%11%-3%-10%-5%0%5%10%15%20%25%Q3 - 22 Q3 - 23 Q3 - 24 Q3 - 25 Q3 - 26EBIDTAPBT
Page 5
P&L Analysis – Gross Margin % to Sales Q3 41%40%45%43%31%0%5%10%15%20%25%30%35%40%45%50%Q3-22 Q3-23 Q3-24 Q3-25 Q3-26
Page 6
P&L Analysis – Exp. % to Sales Q3 10%10%9%10%11%22%21%20%20%18%0%5%10%15%20%25%Q3-22 Q3-23 Q3-24 Q3-25 Q3-26 Emp BenefitOther Exp
Page 7
Thank You